OBJECTIVES: The purpose of this medico-economic study is to estimate cost-effectiveness impact of treating the patients suffering from venous leg ulcers in France. Outpatient treatment with soft-adherent foam dressing with TLC-NOSF a healing accelerator technology (Lipido-Colloid Technology, TLC, with Nano-OligoSaccharide Factor, NOSF) was compared to the identical dressing without NOSF compound (neutral foam dressing). METHODS: A lifetime Markov model based on three states: “Patient with more than 6 months venous leg ulcer”, “Patient with healing ulcer” and “Death”.  The healing process is represented by a law of Gompertz. The probability of recurrences is considered. Monte Carlo simulation of 1000 patients was applied to compare face to face the situations which were not experimentally tested. An intermediate endpoint of effectiveness was healing rate of ulcers during 8 weeks. A final health outcome was life-years gained without ulcers. We have estimated the direct costs associated with material costs, medical consultation and nursing care. This evaluation takes into account both health insurance and health care system perspectives in France. Clinical and economic outcomes were discounted at 4%. RESULTS: The number of life-years gained without ulcer is +5.8 (CI95% : [+5.5;+6.0]) years comparing with the dressing without NOSF. Additional QALY gain is 1.3 [CI95% : 1.2; 1.3]. According to health care system perspective, the mean cost per patient at lifetime period is €20119,322 [CI95% : €8,725; €9,920] comparing with €18,352 [CI95% : €17,807; €18,897] using the dressing of reference. The probabilistic sensitivity analysis of 10,000 bootstrapping samples was performed comparing two strategies. The estimated probability shows 100% of acceptability of the treatment with TLC-NOSF technology. CONCLUSIONS: According to the base case hypotheses the innovational strategy TLC-NOSF is more effective and less costly than the reference dressing (neutral foam dressing).